|
|||||
|
|

Insurance specialty broker Ryan Specialty (NYSE:RYAN) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 13.2% year on year to $751.2 million. Its non-GAAP profit of $0.45 per share was 8.3% below analysts’ consensus estimates.
Is now the time to buy RYAN? Find out in our full research report (it’s free for active Edge members).
Ryan Specialty’s fourth quarter results were met with a negative market response, reflecting investor concerns over the company’s margin pressures and a revenue shortfall versus Wall Street expectations. Management attributed the softer quarter to a sharp downturn in property pricing, especially for large accounts, and persistent delays in project-based construction business. CFO Janice Hamilton emphasized, “The fourth quarter really marked an intensification of some of these property pricing trends,” noting rate decreases of up to 35% in certain areas. Management also pointed to increased investments in talent and technology as factors weighing on profitability.
Looking forward, Ryan Specialty’s guidance is shaped by ongoing headwinds in property pricing and a moderating pace of growth in casualty lines. Management underscored their expectation for high single-digit organic revenue growth in 2026, supported by diversified specialty offerings and the potential for operational savings from the new Empower restructuring program. CEO Timothy Turner highlighted, “We believe there’s plenty of new business for us to capture this year,” while also acknowledging macroeconomic uncertainty and continued investment needs. The company’s ability to execute on efficiency initiatives and adapt to evolving insurance market dynamics will be key to meeting its targets.
Management attributed Q4’s performance to intensified property market volatility, margin compression from investments, and complex integration following recent acquisitions.
Ryan Specialty’s outlook for 2026 hinges on navigating continued property pricing pressure, operational efficiency gains, and capturing specialty market growth.
In upcoming quarters, the StockStory team will be watching (1) the pace and impact of Project Empower’s efficiency initiatives and related cost savings, (2) trends in property pricing and whether the company can offset declines with new business wins in specialty lines, and (3) the integration and performance of recently acquired businesses, particularly in delegated authority and reinsurance. Progress on talent integration and the effectiveness of technology investments will also be important markers.
Ryan Specialty currently trades at $39.34, down from $44.38 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.
The names generating the next wave of massive growth are right here in our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
| Feb-15 | |
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-13 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Feb-11 | |
| Feb-11 | |
| Feb-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite